Array BioPharma, Novartis deal

The companies will terminate a 2010 deal granting Novartis exclusive, worldwide rights to oncology candidate binimetinib. Novartis will pay Array $85 million up front and continue to conduct

Read the full 288 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE